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Summary
Autosomal dominant cerebellar ataxia type III (ADCA
III) is a relatively benign, late-onset, slowly progressive
neurological disorder characterized by an uncomplicated
cerebellar syndrome. Three loci have been identified: a
moderately expanded CAG trinucleotide repeat in the
SCA 6 gene, the SCA 5 locus on chromosome 11, and
a third locus on chromosome 22 (SCA 10). We have
identified two British families in which affected individ-
uals do not have the SCA 6 expansion and in which the
disease is not linked to SCA 5 or SCA 10. Both families
exhibit the typical phenotype of ADCA III. Using a ge-
nomewide searching strategy in one of these families, we
have linked the disease phenotype to marker D15S1039.
Construction of haplotypes has defined a 7.6-cM inter-
val between the flanking markers D15S146 and
D15S1016, thereby assigning another ADCA III locus
to the proximal long-arm of chromosome 15 (SCA 11).
We excluded linkage of the disease phenotype to this
region in the second family. These results indicate the
presence of two additional ADCA III loci and more
clearly define the genetic heterogeneity of ADCA III.
Introduction
Autosomal dominant cerebellar ataxias (ADCA) consti-
tute a group of neurodegenerative disorders that can be
classified clinically into three major categories (Harding
1993). ADCA type I (ADCA I) is characterized by ataxia
variably associated with other neurological features, in-
cluding involvement of the central and/or peripheral
nervous system. Linkage studies identified four loci, on
chromosome 6, 12, 14, and 16, and three genes, SCA 1
(MIM 164400), 2 (MIM 183090), and 3 (MIM
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109150), have been cloned (Orr et al. 1993; Kawaguchi
et al. 1994; Flanigan et al. 1996; Imbert et al. 1996;
Pulst et al. 1996; Sanpei et al. 1996). ADCA type II
(ADCA II; MIM 164500) is distinguished clinically by
the presence of a pigmentary macular dystrophy (Har-
ding 1982, 1993) and by the variability in the mode of
presentation and striking anticipation. Affected individ-
uals in most ADCA II families have a trinucleotide-re-
peat expansion in the SCA 7 gene (Giunti et al. 1999).
The focus of the present study is ADCA type III
(ADCA III; MIM 117210), which is characterized by a
relatively pure cerebellar syndrome and is genetically
heterogeneous. To date, three loci have been identified.
The SCA 6 (MIM 183086) CAG-repeat expansion (Zhu-
chenko et al. 1997) on chromosome 19 is responsible
for ∼50% of British ADCA III families (P. Giunti, P. F.
Worth, M. G. Sweeney, and N. W. Wood, unpublished
data). In addition, linkage of the disease phenotype in
two families to loci on chromosome 11 (SCA 5; MIM
600224; Ranum et al. 1994) and chromosome 22q (SCA
10; MIM 603516; Zu et al. 1999) has been reported.
The clinico-genetic classification of the ADCAs is sum-
marized in table 1.
We have identified two British ADCA III families in
which affected individuals do not have expansions in the
SCA 1, 2, 3, 6, or 7 genes and in which the disease
phenotype is not linked to SCA 4, SCA 5, or SCA 10.
To identify the ADCA III loci in these families, we have
used a genomewide linkage analysis. Here, we report
evidence of linkage of the disease phenotype in one of
these families to a novel locus on chromosome 15q and
provide further evidence of genetic heterogeneity in this
condition.
Families and Methods
This study was approved by the Ethics Committee of
the Institute of Neurology. Informed consent was ob-
tained from all individuals who participated.
Family 1
Figure 1 shows a simplified and abbreviated genea-
logical tree for family 1, with seven of the eight gener-
ations ascertained. Detailed clinical examination has
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Table 1
Clinico-Genetic Classification of ADCA
ADCA
Type Clinical Features Genetic Loci and Chromosomal Location
I Cerebellar syndrome plus pyramidal signs, supranuclear
ophthalmoplegia, extrapyramidal signs, and dementia SCA 1 6p2223; SCA 2 12q2324.1; SCA 3 14q32.1; SCA 4 16q24ter
II Cerebellar syndrome plus pigmentary maculopathy SCA 7 3p12-21.1
III “Pure” cerebellar syndrome; mild pyramidal signs SCA 5 Cent 11; SCA 6 19p13; SCA 10 22q; SCA 11 15q14-21.3
NOTE.—SCA genes that have been cloned are underlined.
been done in 14 affected subjects. In each of the other
three affected individuals, more than one family inform-
ant has confirmed affected status and has supplied age-
at-onset data. DNA samples are available from 17 of
30 affected subjects, six at-risk subjects, and five unaf-
fected spouses. There are no asymptomatic obligate car-
riers. Male-to-male transmission is observed in this fam-
ily. Student’s t-test was used for comparison of mean
ages at onset.
Family 2
Family 2 is a four-generation pedigree with eight af-
fected individuals (fig. 2). DNA is available from seven
affected subjects, six at-risk subjects, and two unaffected
spouses. Detailed clinical examination has been done in
five affected subjects; one other subject experienced sub-
jective unsteadiness, and a computed tomography (CT)
scan showed moderate cerebellar atrophy. In the seventh
affected member, no clinical details were available, but
a family informant gave age-at-onset information.Male-
to-male transmission was observed.
DNA Analysis
DNA was extracted from blood leukocytes with use
of conventional methods. Affected subjects from both
families do not have expansions in the SCA 1, 2, 3, 6,
or 7 genes, and linkage of the disease to the SCA 4
(D16S422 and D16S289), SCA 5 (D11S903 and
D11S905), and SCA 10 (D22S274) loci has been ex-
cluded (data not shown). To exclude point mutations in
the SCA 6 gene, linkage to this locus was excluded with
use of both the SCA 6 intronic marker D19S1105 and
the polymorphic SCA 6 CAG repeat, which, although
in the normal range, was sufficiently informative in these
families (data not shown).
The Linkage Mapping Set Version 2 (Applied Bio-
systems) consists of ∼400 fluorescently labeled primers
that are used to amplify highly polymorphic chromo-
some-specific microsatellite markers, mostly from the
Ge´ne´thon map (Dib et al. 1996). PCR was done with
the GeneAmp PCR system, with a total volume of 7.5
ml containing the following reagents: 10% PCR Buffer
II, 2.5 mM MgCl2, 0.25 mM each dNTP, 2.5 pmol each
primer, 30 ng DNA, and 0.3 U AmpliTaq Gold. Samples
were subjected to an initial denaturation step of 95C
for 12 min; followed by 10 cycles of 94C for 15 s, 55C
for 15 s, and 72C for 30 s; and then a further 20 cycles
of 89C for 15 s, 55C for 15 s, and 72C for 30 s. A
final extension of 10 min at 72C was specified.
GeneAmp 9700 thermal cyclers were used.
Samples were run on 4% polyacrylamide gels with an
ABI 377 automated sequencer equipped with GENE-
SCAN (v. 3.1). Alleles were sized with GENOTYPER
(v. 2.0).
Linkage Analysis and Haplotype Analysis
Using SLINK (Ott 1989; Weeks et al. 1990) with four
alleles of equal frequency, we calculated maximum ex-
pected LOD scores for each family. For family 1, a max-
imum LOD score of 4.90 at recombination fraction
(v).00 was obtained, with an 80% chance of obtaining
a LOD score 1 3.0 For family 2, the maximum LOD
score was 1.43 ( ). For this reason, we have notv  .00
undertaken a separate genome search in family 2.
Two-point LOD scores were computed for each
marker with use of MLINK (Lathrop et al. 1984; Cot-
tingham et al. 1993) of the FASTLINK (v. 3.0P) package.
The disease was assumed to be autosomal dominant
with a disease-allele frequency of .0001. Equal marker-
allele frequencies were assumed. Only affected individ-
uals and unaffected spouses were included in the linkage
analysis. After the initial screen, we typed unaffected at-
risk individuals to determine haplotypes but did not in-
clude them in the LOD-score calculations. Haplotypes
were assigned manually, to insure that the smallest num-
ber of recombination events was inferred.
Results
Subjects
In family 1, mean age at onset was years24.7 8.3
(range 15–43 years, ), and yearsn  17 37.6 18.2
(range 20–70 years, ) in family 2. Statistically sig-n  7
nificant anticipation with respect to age at onset was not
observed in family 1, in which mean ages at onset for
generations IV–VII were 29.3 years ( ), 22 yearsn  3
( ), 25.7 years ( ), and 24 years ( ), re-n  5 n  7 n  2
spectively. There was no significant difference between
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Figure 1 Abbreviated genealogical tree for family 1. Birth order has been changed and gender concealed in those individuals denoted by
a diamond shape, to maintain the anonymity of the family. Unaffected at-risk individuals are not shown. Affected status is denoted by blackened
symbols. An asterisk (∗) denotes individuals for whomDNA samples are available. Haplotypes for chromosome 15markers are shown;haplotypes
cosegregating with the trait are boxed. Alleles in parenthesis are those for which phase could not be assigned with certainty. Dashes are used
if the marker could not be typed. Informative recombination events place the SCA 11 disease locus between markers D15S146 and D15S1016.
these means (generation IV and V, ; generationP  .34
V and VI, ; and generation VI and VII,P  .50 P 
). However, one subject, whose age at onset was 15.68
years, developed the disease before her mother who de-
veloped the disease at age 35 years. In family 2, evidence
of anticipation could not be determined because of the
small number of subjects.
The phenotype was similar in all affected subjects
from both families and is that of a relatively “pure,”
slowly progressive, benign cerebellar syndrome, with no
evidence of significant involvement of other central or
peripheral nervous systems, consistent with ADCA III.
Subjects in both families have normal life expectancy,
with mean age at death years (range70.6  13.7
55–88 years, ) in family 1 and yearsn  8 74 5.7
(range 70–78 years, ) in family 2. The major phe-n  2
notypic features of both families are summarized and
compared in table 2. Mild hyperreflexia (with negative
Babinski sign) was found in all affected subjects from
family 1 but in none from family 2. In addition, vertical
nystagmus was present in 57% of affected members of
family 1 but in none of family 2. The mean disease
duration at examination in family 1 was 23.9 13.4
years. No ophthalmoplegia, lower motor-neurone signs,
or extrapyramidal features were observed in either fam-
ily. Two affected subjects aged 175 years from family 2
had mild loss of deep sensation. No affected subjects in
either family were wheelchair-bound.
Investigations
In family 1, nerve-conduction studies and electro-
myography were normal in three affected subjects. One
other affected subject, aged 61 years (disease duration
29 years), had slightly small sensory action potentials
(SAPs). Magnetic resonance imaging brain scans on
three affected subjects showed isolated cerebellar atro-
phy. In family 2, a CT brain scan in one subject showed
cerebellar atrophy. These results are characteristic of
ADCA III.
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Figure 2 Abbreviated pedigree of family 2. Notation is the same as for figure 1. Affected individuals clearly have different haplotypes,
thus excluding linkage of the disease to the SCA 11 locus in family 2.
Linkage Analysis (Family 1)
Microsatellite markers (350) were analyzed in family
1 before linkage to D15S994 and D15S978 was iden-
tified, with maximum LOD scores of 4.41 and 4.48,
respectively, at . Additional markers in this re-v  .00
gion were then analyzed. Two-point LOD scores for
family 1 are shown in table 3. A maximum LOD score
of 4.67 ( ) was obtained with marker D15S1039.v  .00
Small discrepancies exist between the various marker
maps (Robinson et al. 1997), but the Ge´ne´thon map
places the markers in the following order: D15S1012-
4.6 cM-D15S146-0.5 cM-D15S994-0.0 cM-D15S968-
5.5 cM-D15S123-0.0 cM-D15S1039-0.0 cM-D15S978-
1.6 cM-D15S1016-3.1 cM-D15S998-0.6 cM-D15S117-
6.9 cM-D15S1036-4.4 cM-D15S153. Distances are sex-
averaged.
Haplotype Analysis
Affected recombinants in family 1 place the locus
within a 7.6-cM region on chromosome 15q14-21.3,
between D15S146 and D15S1016 (fig. 1). This locus has
been designated “SCA 11,” after approval was given by
the Human Genome Nomenclature Committee. A total
of six unaffected at-risk individuals have been typed for
the above markers, and five do not have the disease-
associated haplotype (data not shown). Two of these
subjects are 10 years older than the maximum age at
onset observed in affected individuals, whereas the ages
of the other three are within the age-at-onset range. An-
other unaffected subject, aged 34 years (i.e., within the
age-at-onset range), carried the disease haplotype (data
not shown), but this subject is not shown in figure 1, to
maintain confidentiality. Moreover, these individuals do
not help to define further the disease locus.
Linkage and Haplotype Analysis (Family 2)
Once linkage to the SCA 11 locus was established in
family 1, individuals in family 2 were typed for the same
markers. Two-point LOD scores are given in table 4.
Figure 2 shows a haplotype analysis in family 2. Affected
members have different haplotypes. Taken together,
these data exclude linkage to the SCA 11 locus and pro-
vide evidence for a further ADCA III locus.
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Table 2
A Comparison of the Clinical Features of Family 1 and 2
Clinical Feature Family 1 Family 2
Disease duration (years)
a
23.913.4 )
Age at onset (years) a 24.78.3 37.618.2
No. of Subjects (%)
Gait ataxia 14 (100) 5 (100)
Eye movements:
Jerky pursuit 14 (100) 5 (100)
Ophthalmoplegiab 0 (0) 0 (0)
Slow saccades 0 (0) 0 (0)
Limb ataxia 13 (93) 5 (100)
Dysarthria 14 (100) 4 (80)
Horizontal nystagmus 14 (100) 2 (40)
Hyperreflexia 14 (100) 0 (0)
Vertical nystagmus 8 (57) 0 (0)
Diplopia 1 (7) 1 (20)
Positive Babinski 0 (0) 0 (0)
Fasciculations 0 (0) 0 (0)
Loss of deep sensation 0 (0) 2 (40)c
Extrapyramidal signs 0 (0) 0 (0)
a Mean  SD.
b Ophthalmoplegia includes both supranuclear and nuclear.
c Loss of deep sensation was very mild in these two individuals,
both aged 175 years.
Table 3
Two-Point LOD Scores Between the SCA 11 Locus in Family 1 and Microsatellite
Markers on Chromosome 15
MARKER
LOD SCORE AT v 
.00 .001 .01 .05 .100 .200 .300 .400
D15S1012 .81 .23 1.12 1.51 1.43 .98 .49 .15
D15S146 .94 .09 .99 1.40 1.34 .95 .53 .21
D15S994 4.41 4.40 4.31 3.93 3.45 2.46 1.49 .65
D15S968 4.24 4.23 4.15 3.76 3.26 2.24 1.23 .40
D15S123 2.50 2.50 2.44 2.19 1.88 1.27 .72 .29
D15S1039 4.67 4.66 4.57 4.15 3.62 2.53 1.49 .62
D15S978 4.48 4.48 4.39 4.01 3.52 2.53 1.54 .67
D15S1016 .14 .13 .11 .44 .63 .61 .43 .21
D15S998 5.76 4.69 2.82 .99 .37 .00 .06 .04
D15S117 4.06 2.75 1.61 .19 .28 .39 .24 .09
D15S1036 .46 1.51 2.39 2.71 2.54 1.87 1.10 .42
D15S153 12.50 8.91 4.66 1.50 .40 .28 .33 .17
Discussion
Our data clearly establish the existence of two addi-
tional loci for ADCA III; one on chromosome 15q and
another locus, which at present remains undefined. In
family 1, we obtained a two-point LOD score of 4.67
with marker D15S1039 ( ). Haplotype analysisv  .00
defined a 7.6-cM region between D15S146 and
D15S1016 on 15q14-21.3. We genotyped a total of six
unaffected at-risk individuals and found that five did not
carry the disease-associated haplotype. Two of these sub-
jects are 110 years older than the maximum age at onset
observed in affected individuals, whereas the ages of the
three other at-risk subjects were within the age-at-onset
range. One unaffected subject, aged 34 years, had the
disease haplotype. In family 2, we excluded linkage to
markers D15S146–D15S1016, but this family is not
large enough to define a new locus.
ADCA III is a relatively benign, slowly progressive,
late-onset cerebellar syndrome, and the absence of in-
volvement of other major systems (e.g., pyramidal, ex-
trapyramidal, bulbar, or peripheral neuropathy) is
characteristic (Harding et al. 1982, 1993). Three loci for
ADCA III have been identified to date. A moderately
expanded CAG repeat has been found in the SCA 6 gene
on chromosome 19. This gene codes for the a1A sub-
unit of the voltage-gated calcium channel (Zhuchenko
et al. 1997) and results in an expanded polyglutamine
tract in the C-terminal domain. This expansion has been
shown to segregate with the disease phenotype in ∼50%
of ADCA III families investigated in this laboratory (P.
Giunti, P. F. Worth, M. G. Sweeney, and N. W. Wood,
unpublished data). The disease phenotype in a single
family has been linked to the SCA 5 locus on chromo-
some 11 (Ranum et al. 1994), and Grewal et al. (1998)
recently have described a family ofMexican descentwith
the clinical phenotype of ADCA III. Zu et al. (1999)
subsequently have shown linkage of the disease in this
family to a third ADCA III locus on chromosome 22q
(SCA 10).
Although affected individuals in family 1 and 2 did
not have an expansion in the SCA 6 gene, we excluded
linkage to SCA 6 by using marker D19S1105 and the
(CAG)n repeat in the SCA 6 gene to rule out point mu-
tations at this locus. Point mutations in SCA 6 have been
shown to account for families with episodic ataxia type
2, which may show a progressive ataxic phenotype
(Zhuchenko et al. 1997).
The mean age at onset in family 1 was 24.7 8.3
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Table 4
Two-Point LOD Scores Between the ADCA III Locus in Family 2 and Microsatellite
Markers on Chromosome 15
LOD SCORE AT v 
MARKER .00 .001 .01 .05 .1 .2 .3 .4
D15S146 6.25 4.41 2.60 1.26 .72 .24 .04 .02
D15S994 6.24 4.39 2.59 1.25 .71 .24 .04 .02
D15S968 9.97 6.95 4.18 2.16 1.33 .58 .23 .05
D15S123 3.08 2.35 1.44 .76 .47 .21 .08 .02
D15S1039 6.26 4.64 2.87 1.51 .94 .42 .17 .04
D15S978 6.25 4.33 2.53 1.20 .66 .20 .01 .04
D15S1016 6.28 4.36 2.57 1.23 .68 .21 .02 .04
years (range 15–43 years), which is considerably earlier
than that of the series of SCA 6 expansion–positive sub-
jects reported to date, with mean ages at onset having
a range of 43–52 years (Geschwind et al. 1997; Mat-
sumura et al. 1997; Matsuyama et al. 1997; Stevanin et
al. 1997; Scho¨ls et al. 1998; Yabe et al. 1998). However,
it should be noted that the ranges overlap. The mean
age at onset in family 2 was intermediate, between that
of family 1 and that of SCA 6 ( years). These37.6 18.2
differing ages at onset are consistent with the observed
genetic heterogeneity. The overall mean age at onset in
the SCA 10 family was not given by the authors, but
mean ages at onset for three successive generations were
42, 34.2, and 15.6 years, respectively (Grewal et al.
1998). Therefore, the overall mean age at onset in SCA
10 may also lie somewhere between that of SCA 6 and
that of family 1. Life expectancy is not shortened in
family 1 or 2 with mean ages at death of 70.6 13.7
and years, respectively.74 5.7
Family 1 and family 2 show the typical phenotype of
ADCA III, which does not differ from that of SCA 6
CAG expansion–positive subjects or from that linked to
SCA 10 (Grewal et al. 1998; Zu et al. 1999). A prom-
inent cerebellar syndrome was common to all subjects,
and the only noncerebellar signs observed were mild
hyperreflexia (with a negative Babinski sign) and vertical
nystagmus, in 57% of family 1. Therefore, clinical ex-
amination alone cannot reliably distinguish among the
phenotypes of family 1, family 2, and SCA 6-positive
ADCA III subjects. Investigations were as expected for
ADCA III and revealed isolated cerebellar atrophy in
three subjects from family 1 and in one from family 2.
Neurophysiology showed small SAPs in one subject from
family 1, aged 61 years, with disease duration of 29
years.
The phenomenon of anticipation is characteristic of
most trinucleotide-repeat disorders except SCA 6, in
which neither dramatic anticipation nor significant mei-
otic instability has been observed. The SCA 10 Mexican
family reportedly exhibits anticipation with respect to
age at onset, which has led researchers to suggest a tri-
nucleotide repeat as the underlying pathogenic mecha-
nism (Grewal et al. 1998; Zu et al. 1999). One individual
in family 1 reported that she became affected before her
mother, although statistically significant anticipation
was not observed. Furthermore, there was no evidence
of anticipation with respect to phenotypic severity.How-
ever, despite these observations, we cannot exclude the
possibility that the mutational mechanism in the disease
gene on chromosome 15q is a trinucleotide-repeat ex-
pansion, especially given the relatively small number of
subjects.
In summary, these data more clearly define the genetic
heterogeneity of ADCA III in accordance with that ob-
served in ADCA I. Our analysis has defined a 7.6-cM
region on chromosome 15 containing a novel ADCA III
locus, designated SCA 11. This region of the genome
spans 18 Mb, determined on the basis of the physical
map of the region, with ∼80% covered by existingYACs.
However, this region is not well defined, and the lack
of consensus between the marker maps suggests that this
estimate may not be particularly accurate. A large num-
ber of ESTs (150) and known genes have been mapped
to this region, but none of those identified represents an
obvious candidate for SCA 11. A further refinement of
the locus in conjunction with physical-mapping studies,
possibly aided by the repeat-expansion–detection
method (Schalling et al. 1993) could enable us to identify
this novel ADCA III locus.
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